Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tango Therapeutics Inc.

1.95
+0.0000
Post-market: 1.950.00000.00%18:58 EDT
Volume:405.24K
Turnover:791.38K
Market Cap:210.81M
PE:-1.63
High:2.04
Open:1.95
Low:1.92
Close:1.95
Loading ...

Tango Therapeutics (TNGX) Receives a Buy from Barclays

TIPRANKS
·
02 Mar

Tango Therapeutics Full Year 2024 Earnings: Revenues Disappoint

Simply Wall St.
·
28 Feb

Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
27 Feb

BRIEF-Tango Therapeutics Q4 Basic EPS USD -0.35

Reuters
·
27 Feb

Tango Therapeutics Q4 Basic EPS USD -0.35

THOMSON REUTERS
·
27 Feb

Press Release: Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights

Dow Jones
·
27 Feb

One Tango Therapeutics Insider Raised Stake By 400% In Previous Year

Simply Wall St.
·
08 Feb

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

GlobeNewswire
·
30 Jan

Is Tango Therapeutics (NASDAQ:TNGX) In A Good Position To Invest In Growth?

Simply Wall St.
·
05 Dec 2024

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
03 Dec 2024

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
03 Dec 2024

Tango Therapeutics treatment of pancreatic cancer granted orphan designation

TIPRANKS
·
27 Nov 2024

Tango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge Funds

Insider Monkey
·
23 Nov 2024

B. Riley Adjusts Price Target on Tango Therapeutics to $8 From $16, Maintains Buy Rating

MT Newswires Live
·
11 Nov 2024

Tango Therapeutics Inc : Guggenheim Cuts Target Price to $8 From $18

THOMSON REUTERS
·
07 Nov 2024

Barclays Keeps Their Buy Rating on Tango Therapeutics (TNGX)

TIPRANKS
·
07 Nov 2024